Saturday 17 October 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024. In the quarter to June 2026, EPS fell 41.6% and free cash flow fell 37.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
24.67
0.73
−2.87%
Follow ZBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (27.99) | |
P/B ratio |
— | — | — | 6.48 | |
Price to Tangible BV |
— | — | — | 6.48 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (5.96) | |
EV/FCF |
— | — | — | (5.96) | |
Quick Ratio |
5.55 | 5.48 | 11.73 | 9.77 | |
Current Ratio |
5.66 | 5.61 | 11.94 | 9.93 | |
Net Debt/EBITDA |
4.14 | 1.11 | 4.74 | 2.36 | |
Debt/Assets |
22.67% | 20.50% | 46.89% | 55.40% | |
Debt/Equity |
0.37 | 0.32 | 1.04 | 1.57 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.22 | 0.93 | 0.51 | |
Capex/Depreciation |
0.00 | 0.00 | (0.33) | 0.00 | |
Interest Coverage |
— | — | (11.66) | (10.45) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 6,291.30% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,574.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 861.90% | |
Graham Net Nets |
— | — | — | 0.12 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (35.42%) | |
Free Cash Flow Yield |
— | — | — | (14.11%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.02 | |
Operating CF per Share |
(0.98) | (1.17) | (1.35) | (0.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.98) | (1.17) | (1.35) | (0.91) | |
Cash per Share |
6.90 | 7.67 | 12.89 | 10.19 | |
Shareholders Equity per Share |
4.66 | 5.41 | 6.04 | 3.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.66 | 5.41 | 6.04 | 3.92 | |
Free Cash Flow |
(41.12) | (52.41) | (75.20) | (57.24) | |
Working Capital |
244.22 | 288.52 | 669.00 | 587.98 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
171.05 | 209.68 | 318.31 | 199.20 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
10.76 | 12.12 | 14.48 | 7.76 | |
Average Assets |
362.73 | 376.80 | 540.72 | 497.39 | |
Average Common Equity |
277.93 | 277.30 | 310.07 | 243.36 |
Columns are period end dates